September 12, 2024 10:22 AM EDT
R&D

Ful­crum's Phase 3 for old GSK drug fails, stock sinks

Max Gelman

Senior Editor

Ful­crum Ther­a­peu­tics re­port­ed a Phase 3 fail Thurs­day morn­ing, send­ing its stock plum­met­ing.

The biotech said that a study test­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times